TAESGP, EFPIA and Medicines for Europe are pleased to share their reflections on EMA-HMA-EC Key principles for electronic Product Information (ePI).

 This paper aims to highlight key asks and identify key actions in order to move the ePI project from principles to action. It also stresses the fact that all stakeholders would benefit from an ePI implementation (industry, health authorities, health care professionals, patients and environment).

 In addition, this paper intends to summarize what would be needed, to deliver easily accessible and up-to-date medicinal product information to patients and health care professionals (HCPs), contributing to the overall health literacy of EU citizens.

 Finally, it also addresses points raised on ePI in the publication of the European medicines agencies network strategy for 2025 and the more recent Pharmaceutical Strategy for Europe. 

 The full paper can be accessed here. 

 Medicines for Europe

Medicines for Europe represents the generic, biosimilar and value-added medicines industries across Europe. Its vision is to provide sustainable access to high quality medicines, based on 5 important pillars: patients, quality, value, sustainability and partnership. Its members directly employ 190,000 people at over 400 manufacturing and 126 R&D sites in Europe and invest up to 17% of their turnover in R&D investment. Medicines for Europe member companies across Europe are both increasing access to medicines and driving improved health outcomes. They play a key role in creating sustainable European healthcare systems by continuing to provide high quality, effective generic medicines, whilst also innovating to create new biosimilar medicines and bringing to market value added medicines, which deliver better health outcomes, greater efficiency and/or improved safety in the hospital setting for patients. For more information please follow us at www.medicinesforeurope.com and on Twitter @medicinesforEU.